PDAC Organoids & Stromal Desmoplasia Assays

The Desmoplastic Barrier: Engineering the Physical Shield

In clinical PDAC, the actual neoplastic cells represent only a minor fraction of the total tumor volume, often less than 20%. The remainder is composed of a dense, fibrotic, and cellular matrix known as the stroma, generated by a profound desmoplastic reaction. This dense extracellular matrix (ECM) acts as a physical shield, raising interstitial fluid pressure (IFP) to levels that compress local blood vessels, severely restricting the convective delivery of standard chemotherapeutics like gemcitabine and nab-paclitaxel.

Traditional flat two-dimensional (2D) monocultures of pancreatic cancer cells entirely miss this biophysical gating. Even isotropic 3D spheroids fail to capture the mechanical tension, spatial gradients, and cellular heterogeneity of the native tissue. Our microfluidic-integrated PDAC-on-a-chip systems address this gap by establishing compartmentalized architectures where we can tune matrix stiffness, control perfusion rates, and introduce active cellular partners to evaluate both stromal exclusion and drug penetration mechanics.

Biophysical Anatomy of PDAC Desmoplasia

To reconstruct desmoplasia in vitro, we analyze the primary constituents of the PDAC ECM. The dominant components include Type I and Type III collagens, heavily cross-linked by lysyl oxidase (LOX) enzymes, alongside highly hydrophilic glycosaminoglycans such as hyaluronic acid (HA) and structural glycoproteins like fibronectin. This complex gelation network creates a high elastic modulus (often exceeding 10 kPa, compared to less than 1 kPa in normal pancreatic tissue), which triggers mechanotransduction pathways in both tumor and stromal cells.

Our biofoundry platform controls this by formulating customizable hydrogel matrices. We utilize collagen-hyaluronic acid interpenetrating networks (IPNs) whose stiffness is dynamically cross-linked using enzymatic or photopolymerizable linkers. By adjusting the ratio of collagen type I to low and high molecular weight hyaluronic acid, we precisely control the mechanical microenvironment. This mechanical stress activates pancreatic stellate cells (PSCs) into alpha-smooth muscle actin (α-SMA) expressing cancer-associated fibroblasts (CAFs).

We distinguish and cultivate two distinct CAF subpopulations in our co-cultures:

• Myofibroblastic CAFs (myCAFs): Situated in close proximity to the organoid boundary, characterized by high α-SMA expression and dense collagen deposition, driving the mechanical stiffening of the matrix.
• Inflammatory CAFs (iCAFs): Located further in the stroma, secretors of high levels of interleukin-6 (IL-6), leukemia inhibitory factor (LIF), and other inflammatory cytokines that modulate immune evasion.

Microfluidic Co-Culture & Perfusion Physics

We deploy multi-channel organ-on-a-chip devices to simulate vascular flow and interstitial diffusion. These chips feature a central organoid-containing hydrogel channel flanked by parallel perfusion microchannels simulating functional microcapillaries. Endothelial cells (HUVECs) line these perfusion channels, forming a semi-permeable biological barrier.

Using computer-controlled syringe pumps and recirculating microfluidic manifolds, we subject the system to physiologically relevant shear stress (typically 0.1 to 0.5 dyne/cm²). This setup allows us to monitor mass transport across the endothelial wall and through the dense stroma. The transport of therapeutics is governed by Fickian diffusion coupled with convective flow. We model this using the classic transport equations:

Where J represents the drug flux, D is the diffusion coefficient within the specific desmoplastic matrix, ∇C is the concentration gradient, and v is the convective velocity vector driven by interstitial fluid flow. By modifying matrix composition and CAF density, we map how changes in the diffusion coefficient D correlate with therapeutic resistance, providing pharmaceutical partners with precise kinetic parameters.

Stromal Gating and Drug Penetration Assays

A key validation step in our drug discovery workflow is the quantification of therapeutic penetration. Standard assays rely on endpoint cell-viability metrics, which obscure whether a drug failed due to intrinsic cellular resistance or a simple failure to reach target cells. Our Biofoundry employs high-resolution live imaging and mass spectrometry to track drug localization in real-time.

We utilize fluorophore-conjugated drug compounds or rely on label-free Multiphoton Excitation (MPE) fluorescence lifetime imaging microscopy (FLIM) to trace drug penetration through the stroma and into the organoid core. Following a defined exposure window, we perform rapid optical clearing of the microfluidic chip using refractive-index-matching agents. We then capture high-resolution 3D z-stacks on confocal or light-sheet microscopes to calculate the radial drug concentration profile:

Here, ψ is the Thiele modulus representing the ratio of reaction rate (cellular drug consumption/metabolism) to diffusion rate. A high Thiele modulus indicates severe mass transport limitations, where the drug is consumed or sequestered at the organoid periphery, leaving the inner core untouched and free to drive tumor recurrence.

Screening for Stromal-Disrupting Therapeutics

The power of the PDAC co-culture system lies in its ability to run dual-targeting screens. We evaluate combination regimens containing:

1. Stromal Modulators: Small molecules or biologics designed to disrupt the ECM or revert CAF activation. Examples include LOX inhibitors (e.g., PXS-5505) to prevent collagen cross-linking, hyaluronidases to degrade HA, and TGF-β receptor antagonists to deactivate CAFs.
2. Cytotoxic/Targeted Payloads: Standard chemotherapeutic regimens (FOLFIRINOX) or targeted small-molecule inhibitors (KRAS G12D/G12V inhibitors).

By administering the stromal modulator prior to or concurrently with the cytotoxic agent, we measure the shift in the therapeutic window. The disruption of stromal integrity is validated by measuring real-time physical parameters: we record local electrical impedance across the gel boundaries using integrated micro-electrodes, which drop significantly as the stromal matrix degrades and allows ion flow.

High-Throughput Automation & Scalability

To make these complex co-cultures viable for industrial drug discovery, we have fully automated the organoid and stroma deposition process. Our robotic liquid handling platforms utilize acoustic droplet ejection (ADE) and low-shear displacement pipetting to handle delicate hydrogel mixtures without triggering premature gelation or mechanical damage to the organoids.

Organoids are automatically sorted by size using inline high-speed optical imagers, ensuring that only uniform organoids within a narrow diameter range (typically 150 ± 20 µm) are dispensed into the chips. Following automated deposition, multi-spectral confocal plate readers perform automated imaging cycles, generating terabytes of raw data that are analyzed using deep learning networks trained to segment live/dead cells, measure extracellular matrix density, and score cellular migration in 3D space.

Through this integration of advanced microfluidics, biomimetic tissue engineering, and robotic automation, we provide an oncology diagnostic and screening engine that bridges the critical translational gap in pancreatic cancer therapy, accelerating the discovery of treatments that can penetrate the dense stroma and eliminate resistant cancer stem cell niches.